I like how you keep comparing OWC Pharmaceutical Research Corp (OWCP) with the 20 year old pharma company GW Pharmaceuticals (GWPH). Yes OWCP is the next GWPH and we are at the ground floor, an investor's dream! The next couple months are going to be exciting, but the next couple of years are going to make serious investors very rich.

$OWCP = BIG MONEY $$$$$$

In reply to the posts on the topic of Form 3 that was filed for Dr. BARUCH YEHUDA.

I-Glow wrote:
"It seems most didn't understand the Form 3"

I refer to a reliable source:
According to SEC.GOV "The initial filing is on Form 3"

-whereas-

According to SEC.GOV "Changes in ownership are reported on Form 4"


In post# 99951 I-Glow wrote:
"If the options hadn't exercised there wouldn't be any need for the Form 3 to be filed. I have no idea what is so difficult to understand."

WRONG!
According to SEC.GOV "The initial filing is on Form 3"

Then I-Glow wrote:
"You don't seem to understand that it has been 2 years.

2. Date of Event Requiring Statement (MM/DD/YYYY)12/22/2014"

WRONG!
Date of Event Requiring Statement: 12/22/2014 refers to the Common Stock in the amount of 2,120,000 shares that were granted to Dr. BARUCH YEHUDA back in 2014. Those shares are also noted on the Form 3 that was filed today.

I was very kind and simply asked you if you had read the 10-K for 2015 and 2016.

I-Glow's reply:
"Of course I read them - if the options hadn't been exercised there wouldn't be a need to file a Form 3. ... Why was the Form 3 filed if the options weren't exercised? You argument is nonsensical - something like he filed the Form 3 just for the hell of it."

WRONG!
According to SEC.GOV "The initial filing is on Form 3"


I mentioned the 2015 10-K because in that 10-K ITEM 12 it states the 2,120,000 shares owned by Dr. BARUCH YEHUDA.

The Form 3 for Dr. BARUCH YEHUDA includes:
Title of Security: Common Stock of 2,120,000 shares (the same shares mention on 2015 10-K).
Title of Derivate Security: Option of 7,000,000 derivative shares (the same EPOs from the ESOP on 2016 10-K).

Link to the Form 3
https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12148644

So there are the facts as stated on the Form 3. All 7,000,000 derivative shares are listed as Options, not Common Stock. If any of the 7,000,000 ESOs had been exercised then they would not be listed as Options so the number of options would be less than 7,000,000 , also the number of Common Stock shares would be more than 2,120,000.


There are many smart investors on this board that do solid DD. This ticker is the best spec stock on the OTC. Of course there are risk with ANY stock. This company is sound with mega potential this year and years to come.

Hope this helps.

$OWCP Longer and Stronger

I don't appreciate you saying I missed the point again and again... total non-sense. I'm saying it as it is.

Most of the management owned shares before the 2016 ESOP - SKIN IN THE GAME !!!

1/3 of 2016 ESOP vested on grant (wether exercised or not) - SKIN IN THE GAME !!!

2/3 of 2016 ESOP to completely vest at the end of 2018 - SKIN IN THE GAME !!!

Any and all stock shares management owns today, tomorrow, 1 year from now, 2 years from now, 10 years from now - SKIN IN THE GAME !!!


$OWCP Longer and Stronger

The recent Form 3 and Form 5 are not about loans.

The stock is related to top managements compensation in the form of a ESOP grant from Dec 2016. Read the last 10-K to read the original disclosure of this ESOP. The stock option by design gives the one who holds the options a PPS that is profitable to the holder, otherwise they would be worthless. This is sound business.

ESOPs are a standard practice to incentivize the management of a company and they work very well.

I haven't misunderstood anything about the ESOP grant of 2016. It was a major plus to this company in my opinion and I was very glad to see it in the last 10-K.

Why obsess about the 1/3 vested on the grant date of December 15, 2016?

The top management have 2/3 more of these ESOs that won't vest until the end of 2018.

What a great incentive for them to continue to meet their goals and bring this ticker to the big boards.

As for the 1/3 in question, once they exercise the option they own the stock. Again, what a great incentive for them to make this stock do well.

I'm absolutely stoked that they have SKIN IN THE GAME !!!!

Thank you for posting your correspondence with IPD@USPTO.GOV about the OWCP patent.

It makes the facts VERY CLEAR.


$OWCP Longer and Stronger

Simple question. Have you read the 10-Ks for 2015 and 2016 ?

Here is the ESOP remarks in the 10-K

(3) Under the Company’s 2016 ESOP, 10 million options were granted to Mr. Bignitz, 750,000 options were granted to Mr. De-Saban, and 7 million options were granted to Dr. Baruch and Mr. Sinai during 2016. Subject to the provisions of applicable Israeli laws, these options are held by a trustee and vest after a period of two years and, as a result, are not included in the above table.

That's it. BINGO

$OWCP is going to make it's longterm investors (including themselves) a lot of money; while helping people alleviate their suffering through a more natural treatment with proven efficacy.

This stock is poised to run hard, and when the day comes that it does those on the sidelines waiting for the next flip will get left behind. We've all been there, that's simply the downside to flipping.

All the down is really sideways as this ticker stair-steps up. The MMs and shorts try and try to scare new investors shaking the tree but there are too many solid hands who have done their DD who believe in this company.

I disagree with what you are saying, however

Even if your interpretation was accurate, which it's not in my opinion, OWCP management still have 2/3 of their ESOs not vested until the end of 2 years which is December 15, 2018.

THAT'S BIGTIME SKIN IN THE GAME.

quick recap for your convenience:

1/3 vested

2/3 not vested

2/3 is more than 1/3

how much more???

a lot more. Like twice as much.

Continuing to strongly confirm that OWCP top management have skin in the game.

1/3 of their ESOs are vested, however: "They may not be exercised within the first two years after the date of grant"

-therefore-

2/3 are not vested

and cannot vest for 2 years after ESOP was issued except that 8.33% of ESOs will vest quarterly.
The ESOP was granted December 15, 2016, and will vest December 15, 2018.

1/3 of their ESOs are vested, however: "They may not be exercised within the first two years after the date of grant". I like the ESOP and was relieved to see it in the last 10-K. Good for them for being compensated since the only salary taken up through Dec 31, 2016 was by the CEO Mordechai Bignitz which amounted to $12,000 for the entire year of 2015 and $36,000 for the year of 2016.


2/3 of their ESOs are not vested and all of the ESOs from this ESOP are restricted. "They may not be exercised within the first two years after the date of grant"... hence they have a lot of skin in the game.

Just like the previous Form 3 and Form 5 it confirms that the top management has skin in the game.

OWCP is the real deal and all of us investors will reap the rewards in the near future and years to come.

LONG AND STRONG $$$$OWCP$$$$

TOPIC: One World Cannabis Pharmaceutical (OWCP), Patent application: 15/639,230
Correspondence from IPD@USPTO.GOV about Patent application: 15/639,230


-----Original Message-----
From: g
Sent: 06/27/17 6:39:54 PM
To: IPD <IPD@USPTO.GOV>
Subject: Patent application

Hi, I'm having trouble finding this patent application that One World Cannabis pharmaceautical (owcp) says they were filing on june 27th 2017. I'm also wondering why the first numbers are 15 and not 17?

15/639,230

Thank you,
G

Sent via the Samsung Galaxy S7, an AT&T 4G LTE smartphone
--------------------------------------------------------------------------------



-----The reply from IPD@USPTO.GOV about Patent application: 15/639,230-----

[THREAD ID:1-8C3K5B]
Dear G,

For the first 18 months after the filing date of a new patent application, the application can only be seen/accessed by the applicant, inventor, or their legal representative via PRIVATE PAIR.

18 months from the filing date (if the applicant/inventor allows it), it will publish (as originally filed, not amended) and be available to the Public. This is also known as pre-grant publication. It would then be available in the USPTO AppFT database.

The first 2 digits of a U.S. patent application are the Series Code which is based on a filing date range of the application. See below:

U.S. Patent Application Series Codes

Code: Filing Dates:

01 Began January 1, 1915
02 Began January 1, 1935
03 Began January 1, 1948
04 Began January 1, 1960
05 Began January 1, 1970
06 Began January 1, 1979
07 Began January 1, 1987
08 Began January 1, 1993
09 Began December 30, 1997
10 Began October 24, 2001
11 Began December 1, 2004
12 Began December 6, 2007
13 Began December 17, 2010
14 Began August 16, 2013
15 Began January 18, 2016

NOTE 1: Series codes were not used prior to 1915. For a patent application prior to 1915 to be uniquely identified, the filing date must be used in addition to the six digit serial number.

NOTE 2: There are some patent applications where the patent application number (two digit series code and six digit serial number) and filing date may not fall within the time periods indicated.

NOTE 3: Certain ranges of patent application serial numbers are allocated to 35 U.S.C. 371 (national stage PCT) applications and other ranges of patent application serial numbers are allocated to 35 U.S.C. 111(a) applications, so it is possible for one type of patent application to start a new series before the other does. For example, a 371 Application No. 14/###,### was received in the Office (USPTO) on August 16, 2013, while 111(a) Application No. 13/###,### was received in the Office on August 26, 2013.

29 Design Patent Applications – Began October 1, 1992

35 Applied to International Design Applications filed under the Hague Agreement – Began May 13, 2015

60 Provisional Applications – Began June 8, 1995

61 Provisional Applications – Began October 22, 2007

62 Provisional Applications – Began May 19, 2014

NOTE 4: It is possible for some series code 62 provisional applications to have earlier filing dates than some series code 61 provisional applications. For example, Application No. 62/###,### has a filing date of May 19, 2014, while Application No. 61/###,### has a filing date of August 13, 2014.

90 Ex Parte Reexamination Request control number (35 U.S.C. 302-307, see the Manual of Patent Examining Procedure MPEP Chapter 2200) – Began July 1, 1981

95 Inter Partes Reexamination Request control number (35 U.S.C. 311-318, see the Manual of Patent Examining Procedure MPEP Chapter 2600) – Between July 27, 2001 and September 15, 2012

96 Supplemental Examination and resulting Reexamination Request control number (35 U.S.C. 257, see MPEP chapter 2800) – Began September 16, 2012

Kindest Regards,
IPD

Why would Sheba post details about R&D on their website? I think most of the research done there is proprietary. Not to mention what a waste of resources that would be. Why would they be wasting time to update clinical trial info on their website so that the public can track the trials, while they are busy conducting clinical trials?


Do you see anywhere on the website that list a comprehensive list of all the clinical trials conducted there?

I'm totally stoked about all the DD I've done. Anyone that wants to call up or email the coordinator for the Research & Development Department at Sheba Medical Center or the IRB Helsinki Committee Coordinator should do just that including yourself, and get to the bottom of this and when you get hard proof and not just empty words, then please come forthwith and save us all.

Here's me providing a link to the contact information of both the above mentioned directors.

Sheba - Research and Development.
Embedded in the website is a bunch of information.
https://rnd.sheba.co.il/Research_Authority

As you say, back up your words, otherwise it's just empty fluff. I just provided you several sources including multiple websites to world class medical institutions to back up my words.

I-Glow wrote:
"And don't repost a OWCP 8-K or press release and think it is research."

I didn't post an 8-K. I assume you can find those as they are kept up to date on OWCP's website:
http://www.owcpharma.com/investors/

I posted a link and text from an article as a source to back up what I'm saying. Fascinating that the article (as well as other OWCP articles) is posted on a Sheba Medical Center (SMC) website.
The fact that Friends of Sheba Medical Center would post that article on their website says a lot. In going to the actual facility and talking to the staff, they had only good things to say about OWC.

Here's the website for Sheba - Research and Development.
Embedded in the website is a bunch of information.
https://rnd.sheba.co.il/Research_Authority

WRONG! AGAIN! here's some OWCP DD.

Sheba Medical Center (SMC) is the largest hospital in Israel and is in collaboration with OWCP. This relationship has been verified in many ways and 100% legit.

Here is a good DD post from "Hoya Saxa". Well worth a read:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=132405443

OWCP's Clinical Studies at Sheba Medical Center (SMC) article (from a SMC affiliated website):
http://www.friendsofsheba.org/owc-looks-to-bring-pharma-grade-cannabis-therapeutics-to-market/

High Quality Clinical Trials

OWC Pharmaceuticals’ clinical studies are being conducted at the Sheba Academic Medical Center in Tel Hashomer, Israel, in full compliance with Helsinki Committee/IRB conventions. Sheba is one of the leading medical centers in the Middle East, and one of only two facilities in Israel with the U.S. Department of Health and Human Services’ federal-wide assurance designation, which provides it with U.S. federal research grants involving human clinical trials.

The Company’s clinical programs are being spearheaded by Dr. Yehuda Baruch, who headed Israel’s national medical marijuana program from 2003 to 2013. Dr. Baruch’s vast experience in both the regulatory and medical aspects of the cannabis industry have been very instrumental in moving OWCP’s clinical programs forward while ensuring full compliance with the terms established under the IRB-approved protocols.


Institutional Review Board (IRB) website:
http://www.tasmc.org.il/sites/en/Research/Clinical-Trials/Pages/Helsinki.aspx#ContactInfo


I-Glow wrote:
"I keep seeing the nonsense about IRB Safety studies - I assume most have no idea about a IRB - it is a Institutional Review Board - every University etc has one.

We know nothing about the IRB in Israel - who it is comprised of - and where is this safety study - so far OWCP is just all big talk.

You guys act like a IRB is some type of international review organization - it isn't."


Doing an ounce of research makes it hard to comprehend how you tell us that most of us "have no idea about a IRB".
I put that statement back to you... I assume you have no idea about what the IRB is.



$OWCP$$ IS BIG MONEY FOR THE BIG BOYS!

LOL... I literally laughed out loud. Thanks

#LOL
#LMAO

Amen.

What you have educated us on is that you are not a patent expert.

Well over volume of 3 million by 11:00 AM.

We will be back in dollar land soon.

LOL...

If you read again the latest news put out yesterday and today, you can read about how OWCP is moving in a smart way to protect their IP. So of course Dr. Yehuda Baruch is not going to publish a journal article until they have the IP protection they feel they need.



PETACH TIKVA, Israel, June 27, 2017 /PRNewswire/ --

OWC Pharmaceutical Research Corp. (OTCQB: OWCP) today announced that its wholly-owned, Israel-based subsidiary, One World Cannabis Ltd. (OWC), has filed a patent application with the United States Patent and Trademark Office for its active cannabinoid-based topical cream. This new patent application follows the previously filed 'provisional' patent application. The added protection that this patent application provides for OWC's intellectual property will enable the Company to accelerate its ongoing discussions and negotiations regarding scientific, medical and commercial collaboration.

Commenting on the filing of the patent application, Mr. Mordechai Bignitz, Chairman and CEO of OWC Pharmaceutical Research, stated, "After we announced the highlights of our pre-clinical efficacy study for our active, cannabinoid-based topical cream, starting with psoriasis, we received numerous inquiries from firms and organizations worldwide interested in purchasing the cream or initiating commercial or scientific collaboration with OWCP. The need to fully protect our intellectual property limited our ability to provide these potential customers and partners with our proprietary data. This proprietary data now includes specifics regarding the formulation of the cream, which consists of cannabinoids and other compounds that facilitate the efficient delivery of the product to infected areas. The filing of this patent application also enables us to discuss with potential customers and partners, the requirements for manufacturing the cream in accordance with the highest global standards that comply with international protocols, and includes specifics regarding required equipment and systems. We look forward to announcing a more specific plan of product launch details in due course."

Further commenting on the milestone, Dr. Yehuda Baruch, the Company's Chief Science Officer and OWC's Director of Research and Regulatory Affairs ,stated, "I am very proud of the extensive research we have done at OWC Pharma. This research dates back to 2014 and also includes the many studies myself and my medical team have conducted while leading the Medical Cannabis Program under the Government of Israel and treating thousands of patients with cannabis for medical purposes over the years. I feel confident our topical cream will be welcome into the Psoriasis community as there are millions who suffer from this disease across the globe."

Dr. Yehuda Baruch's "CURRICULUM VITAE AND LIST OF PUBLICATIONS". He has a massive amount of experience.

https://drive.google.com/file/d/0B3CPcGOCWnIPWl9COWw2RURpMDRoaTZEQzRJcjJSRXFSZmw0/view

Nice! I'm a big fan of your work. This is gapping way too high.

SOLID!

$OWCP is going to new highs this summer.

GONNA BE HUGE!!!

$OWCP long and strong!!!!!

Absolutely! Do your own DD. In my opinion it is very solid and OWCP has HUGE potential in this once-in-a-lifetime emerging market. This is ground floor and OWCP is very undervalued. The process of protecting IP is a process, and OWCP is being very smart in the way they are protecting their IP. By the end of the year this PPS will be long gone.

GO $OWCP!!!!

This ticker is the best MMJ play on the OTC hands down. There are a lot of exciting catalysts in the pipeline for this summer and the rest of 2017.

$OWCP$ = BIG MONEY FOR THE BIG BOYS

Jeff Smurlick is a consultant who lives in Florida. LinkedIn page: https://www.linkedin.com/in/jeffsmurlick/


"On December 16, 2016, the Registrant entered into a Consulting Agreement with Jeff Smurlick, a resident of the State of Florida"
https://marketexclusive.com/owc-pharmaceutical-research-corp-otcmktsowcp-files-an-8-k-entry-into-a-material-definitive-agreement-2/52055/

Jeff Smurlick is the US consultant for OWCP.
"On December 16, 2016, the Registrant entered into a Consulting Agreement with Jeff Smurlick, a resident of the State of Florida"
https://marketexclusive.com/owc-pharmaceutical-research-corp-otcmktsowcp-files-an-8-k-entry-into-a-material-definitive-agreement-2/52055/



MORE RECENT INFO:

Here is a post from Govman a month ago detailing a conversation with him.

OWC Pharmaceutical Research Corp. Enters Into a Strategic Relationship With Germany-Based mediq Innovation Experts
The Initial Objective of the Collaboration is the Introduction of OWC's Active Cannabinoid-Based Topical Psoriasis Cream to the German Market

NEWS PROVIDED BY
OWC Pharmaceutical Research Corp.
31 May, 2017, 07:00 ET

PETACH TIKVA, Israel, May 31, 2017 /PRNewswire/ --

OWC Pharmaceutical Research Corp. (OTC: OWCP) and mediq Innovation Experts (mediq) are pleased to announce an agreement for the introduction of OWCP's active cannabinoid-based topical psoriasis cream to the German market.

Frankfurt, Germany-based mediq has extensive experience, knowledge and a successful track record in enabling Israel-based companies to penetrate the European markets. mediq's objectives for OWCP will consist of both scientific collaboration and most importantly the development of a commercial market for OWCP's proprietary, active cannabinoid-based topical psoriasis cream in Germany.

Commenting on the collaboration with OWCP, Jan Wende, managing director of mediq stated, "We're looking forward to initiating our efforts on behalf of OWCP in Europe, starting in our home market of Germany. Since German laws and regulations allow non-smokable forms of medical cannabis, we believe that OWCP's proprietary cannabinoid-based topical psoriasis cream is the right product at the right time. Furthermore, Germany is the largest European healthcare market and therefore offers the perfect platform to gain local evidence and roll out the concept into other European countries. Our initial focus for OWCP is on the German market, however we're excited about the long-term opportunities throughout Europe, a market with a population of over 740 million."

Alon Sinai, managing director of OWCP's wholly-owned, Israel-based subsidiary, One World Cannabis, also commented on the collaboration with mediq, "The German market is a great opportunity for OWCP. Germany, with its population of over 81 million, and a gross domestic product of over US$3.36 trillion is the largest economy in Europe. Also, potentially beneficial to OWCP is Germany's recent medical cannabis legislation, which currently limits the usage of smokable-products, and which also provides for reimbursement for medical cannabis by the country's healthcare system. mediq is a great partner for OWCP, and we're looking forward to the prospects of a long-term and mutually relationship with the company both regarding the introduction of OWCP's cannabinoid-based psoriasis cream in the German marketplace, but also for the prospects for scientific collaboration in the country."

About OWCP's Active Cannabinoid-Based Psoriasis Cream

Psoriasis is an autoimmune disease that causes red, scaly patches to appear on the skin, and can be associated with other serious health conditions, including diabetes, heart disease and depression. Skin cells in patients with psoriasis grow at an abnormally fast rate, causing a buildup of lesions that tend to burn and itch. While the real cause of psoriasis is not known, genetics are believed to play a major role in its development. According to the National Psoriasis Foundation, psoriasis affects 7.5 million people in the United States.

OWCP has developed a proprietary active cannabinoid-based topical cream for psoriasis management, with the objective of reducing the skin dryness of patients suffering from the disease. The Company previously reported trial results that concluded that after application of the Company's active cannabinoid-based topical cream formulation, there was up to a 70% improvement in a variety of inflammation markers directly associated with psoriasis.

About OWC Pharmaceutical Research Corp.

OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively "OWC" or the "Company") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines.

OWCP is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWCP research is conducted at leading Israeli hospitals and scientific institutions and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids and cannabis-based products for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information visit: http://www.owcpharma.com/

About mediq Innovation Experts

Frankfurt, Germany-based mediq Innovation Experts (mediq) has vast experience in the European healthcare market. Over the past ten years mediq has successfully introduced disruptive technologies and services throughout the continent. The company's deep understanding of the market dynamics, regulatory, and reimbursement structures is a benefit in enabling international healthcare companies to develop European implementation strategies.

mediq's core capabilities include market assessment, strategy development, clinical validation, scientific marketing strategy, and marketing channel development. For more information visit http://innovationexperts.de .

Excellent strategic move by OWCP. This management team is awesome!

Email from OWCP. Thank you!

This ticker is the best MMJ play on the OTC hands down. Their are a lot of exciting catalyst in the pipeline for this summer and the rest of 2017.

$OWCP$ = BIG MONEY FOR THE BIG BOYS

LOL... That's not a patent rejection letter. Also, this PATENT APPLICATION PCT/IL2015/051138 has been updated recently. It actually indicates that there will likely be a patent granted for Multiple Myeloma.

From the "CORRECTED VERSION" as of May 30, 2017
Several claims within the application are patentable.


Box V. Section 1. Statement

Novelty (N) - Claims 3-15,18,23,24,30-40,43,44,68,69,72-75,79-91 - YES

Inventive Step (IS) - Claims 8 - YES

Industrial Applicability (IA) - Claims 1-44,67-91 - YES

paragraph 2.2.12 Regarding claim 8: "Therefor the subject matter of claims 8 is new and inventive."


The "CORRECTED VERSION" can be found here:

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016084075&recNum=7&tab=PCTDocuments&maxRec=8&office=&prevFilter=&sortOption=Pub+Date+Desc&queryString=FP%3A%28one+world+cannabis%29

Document: DATE: 30.05.2017 "(IB/373) International Preliminary Report on Patentability Chapter I"



The patent process is a process. This is not the final version. OWCP will protect their IP. Very smart management in this company.

Longs stand to make a lot of $$$ with OWCP.

GREAT NEWS! Patent process moving forward and looks like they will get a MM patent.

Do your own DD.
Here are awesome points to note found in the following document.

Document: DATE: 30.05.201 "(IB/373) International Preliminary Report on Patentability Chapter I"
found here:
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016084075&recNum=7&tab=PCTDocuments&maxRec=8&office=&prevFilter=&sortOption=Pub+Date+Desc&queryString=FP%3A%28one+world+cannabis%29

page 5 Section 1. Statement

Novelty (N) - Claims 3-15,18,23,24,30-40,43,44,68,69,72-75,79-91 - YES

Inventive Step (IS) - Claims 8 - YES

Industrial Applicability (IA) - Claims 1-44,67-91 - YES



Page 11 paragraph 2.2.12 Regarding claim 8: "Therefor the subject matter of claims 8 is new and inventive."


BOOM - More to come as IP is protected and published!


$OWCP$

That was just a typo.

The 8K clearly states the website for mediq.
http://innovationexperts.de

Here is one of the paragraphs in the 8-K naming the company by the correct name.

"About mediq Innovation Experts

Frankfurt, Germany-based mediq Innovation Experts (mediq) has vast experience in the European healthcare market. Over the past ten years mediqhas successfully introduced disruptive technologies and services throughout the continent. The company's deep understanding of the market dynamics, regulatory, and reimbursement structures is a benefit in enabling international healthcare companies to develop European implementation strategies.

mediq's core capabilities include market assessment, strategy development, clinical validation, scientific marketing strategy, and marketing channel development. For more information visit http://innovationexperts.de. "


I've done a bunch of DD and yea it's the company.


It's a great match :)

BINGO

$$$OWCP$$$

LOL yea, when a company is awarded a patent, that should DEF be taken with a grain of salt.

Smason386 posted this link: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016084075&recNum=7&tab=PCTDocuments&maxRec=8&office=&prevFilter=&sortOption=Pub+Date+Desc&queryString=FP%3A%28one+world+cannabis%29

The document is found there and titled: "(IB/373) International Preliminary Report on Patentability Chapter I" DATE: 30.05.2017

There's more GOOD NEWS regarding the Patentability here:

This is what caught my eye the most:

Page 11 paragraph 2.2.12 Regarding claim 8: "Therefor the subject matter of claims 8 is new and inventive."

The MORE GOOD NEWS

page 5 Section 1. Statement

Novelty (N) - Claims 3-15,18,23,24,30-40,43,44,68,69,72-75,79-91 - YES

Inventive Step (IS) - Claims 8 - YES

Industrial Applicability (IA) - Claims 1-44,67-91 - YES

What I was stoked about reading the last 8K is that OWCP has chosen to do what you are basically suggesting. Making a deal with mediq seems to be an exact effort to get the cream on the market in Germany as soon as they can because it is legal there and while being used there in Germany it can be proved and then brought into the rest of Europe. This is smart IMO. I see no roadblocks to them actually having this available to folks in Germany by the end of Q3.